174 related articles for article (PubMed ID: 37932009)
1. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
Dörner T; Kaul M; Szántó A; Tseng JC; Papas AS; Pylvaenaeinen I; Hanser M; Abdallah N; Grioni A; Santos Da Costa A; Ferrero E; Gergely P; Hillenbrand R; Avrameas A; Cenni B; Siegel RM
Ann Rheum Dis; 2024 Feb; 83(3):360-371. PubMed ID: 37932009
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
Baer AN; Gottenberg JE; St Clair EW; Sumida T; Takeuchi T; Seror R; Foulks G; Nys M; Mukherjee S; Wong R; Ray N; Bootsma H
Ann Rheum Dis; 2021 Mar; 80(3):339-348. PubMed ID: 33168545
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
Juarez M; Diaz N; Johnston GI; Nayar S; Payne A; Helmer E; Cain D; Williams P; Devauchelle-Pensec V; Fisher BA; Giacomelli R; Gottenberg JE; Guggino G; Kvarnström M; Mariette X; Ng WF; Rosas J; Sánchez Bursón J; Triolo G; Barone F; Bowman SJ
Rheumatology (Oxford); 2021 Mar; 60(3):1364-1375. PubMed ID: 32949140
[TBL] [Abstract][Full Text] [Related]
5. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
Dörner T; Posch MG; Li Y; Petricoul O; Cabanski M; Milojevic JM; Kamphausen E; Valentin MA; Simonett C; Mooney L; Hüser A; Gram H; Wagner FD; Oliver SJ
Ann Rheum Dis; 2019 May; 78(5):641-647. PubMed ID: 30826774
[TBL] [Abstract][Full Text] [Related]
6. Sjögren's and non-Sjögren's sicca share a similar symptom burden but with a distinct symptom-associated proteomic signature.
Pucino V; Turner JD; Nayar S; Kollert F; Rauz S; Richards A; Higham J; Poveda-Gallego A; Bowman SJ; Barone F; Fisher BA
RMD Open; 2022 May; 8(1):. PubMed ID: 35589331
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
Liu X; Li X; Li X; Li Z; Zhao D; Liu S; Zhang M; Zhang F; Zhu P; Chen J; Wei W; Lin B; Zhou Y; Chen J; Pang Y; Zhang L; Sun X; Yu Z; Jia Y; Wang J; Sun W; Chiu F; Pang L; Wang G
Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
[TBL] [Abstract][Full Text] [Related]
8. Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren's.
Cooper C; Wratten S; Williams-Hall R; Bookman AAM; Ndife B; Hueber W; Goswami P
Rheumatol Ther; 2022 Dec; 9(6):1499-1515. PubMed ID: 36114443
[TBL] [Abstract][Full Text] [Related]
9. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
Shao Q; Wang S; Jiang H; Liu L
Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
[No Abstract] [Full Text] [Related]
11. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
[TBL] [Abstract][Full Text] [Related]
12. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
[TBL] [Abstract][Full Text] [Related]
13. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.
Bai W; Yang F; Xu H; Wei W; Li H; Zhang L; Zhao Y; Shi X; Zhang Y; Zeng X; Leng X
Trials; 2023 Feb; 24(1):112. PubMed ID: 36793118
[TBL] [Abstract][Full Text] [Related]
14. Development and testing of an alternative responder definition for EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI).
Wratten S; Abetz-Webb L; Arenson E; Griffiths P; Bowman S; Hueber W; Ndife B; Kuessner D; Goswami P
RMD Open; 2023 Mar; 9(1):. PubMed ID: 36931685
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study.
Fisher BA; Szanto A; Ng WF; Bombardieri M; Posch MG; Papas AS; Farag AM; Daikeler T; Bannert B; Kyburz D; Kivitz AJ; Carsons SE; Isenberg DA; Barone F; Bowman SJ; Espié P; Floch D; Dupuy C; Ren X; Faerber PM; Wright AM; Hockey HU; Rotte M; Milojevic J; Avrameas A; Valentin MA; Rush JS; Gergely P
Lancet Rheumatol; 2020 Mar; 2(3):e142-e152. PubMed ID: 38263652
[TBL] [Abstract][Full Text] [Related]
16. Development and Application of the Placebo Response Model in Clinical Trials for Primary Sjögren's Syndrome.
Wang ZZ; Zheng QS; Liu HX; Li LJ
Front Immunol; 2021; 12():783246. PubMed ID: 34868062
[TBL] [Abstract][Full Text] [Related]
17. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
[TBL] [Abstract][Full Text] [Related]
18. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study.
Price E; Bombardieri M; Kivitz A; Matzkies F; Gurtovaya O; Pechonkina A; Jiang W; Downie B; Mathur A; Mozaffarian A; Mozaffarian N; Gottenberg JE
Rheumatology (Oxford); 2022 Nov; 61(12):4797-4808. PubMed ID: 35377447
[TBL] [Abstract][Full Text] [Related]
20. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).
Seror R; Theander E; Brun JG; Ramos-Casals M; Valim V; Dörner T; Bootsma H; Tzioufas A; Solans-Laqué R; Mandl T; Gottenberg JE; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Valesini G; Bartoloni E; Saraux A; Tomsic M; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Vitali C; Mariette X; Bowman SJ;
Ann Rheum Dis; 2015 May; 74(5):859-66. PubMed ID: 24442883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
